Novo Nordisk has been slowly increasing production capacity of its highly ... claims Build-A-Bear ripped off its designs. Build-A-Bear Workshop has left some people scratching their heads with ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Novo Nordisk AS, Perkin Elmer Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%.

The collaboration is designed to combine NanoVation Therapeutics’ lipid nanoparticle technology for RNA delivery to cells outside the liver with Novo Nordisk’s knowledge of cardiometabolic and rare ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.

Senators grilled the top executive of Novo Nordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and diabetes drug Ozempic than it does ...

Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time. AbbVie's fundamentals ...

Lars Jørgensen, chief executive of the Ozempic manufacturer Novo Nordisk, defended the prices ... are expected to significantly increase production capacity for the company’s medicines ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) is a terrific stock for many reasons. The company continues to deliver excellent financial results thanks to a lineup of medicines with incredibly ...

Across the recent three months, 7 analysts have shared their insights on Novo Nordisk NVO, expressing a variety of opinions spanning from bullish to bearish. The following table provides a quick ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...